Latest Articles

Publication Date
Sun Pharma to acquire Organon in US$11bn deal - FemTech World

Sun Pharma to acquire Organon in US$11bn deal FemTech World

Published: June 17, 2026, 10:47 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - beQuoted

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat beQuoted

Published: June 17, 2026, 9 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - The Manila Times

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat The Manila Times

Published: June 17, 2026, 8:29 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - Yahoo Finance Singapore

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat Yahoo Finance Singapore

Published: June 17, 2026, 8:05 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - Dagens industri

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat Dagens industri

Published: June 17, 2026, 7:01 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - Cision News

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat Cision News

Published: June 17, 2026, 7 a.m.
Association between urinary heavy metals, phthalates, phytoestrogens, and polycyclic aromatic hydrocarbons and endometriosis: A cross-sectional study from NHANES 1999 to 2016.

Research on the association between urinary heavy metals, phthalates, phytoestrogens (PEs), polycyclic aromatic hydrocarbons (PAHs), and endometriosis (EM) is limited. Data were from the National Health and Nutrition Examination Survey …

Published: June 17, 2026, midnight
Complex benign gynecology in perimenopause: current evidence and future directions.

Perimenopause is a clinically distinct stage in which abnormal uterine bleeding, fibroids, adenomyosis, endometriosis, and adnexal pathology may require surgical evaluation. Management is complex because symptom burden and structural disease …

Published: June 17, 2026, midnight
Cross-Platform Comparison of Hugo RAS and da Vinci Xi in Benign Robotic Hysterectomy: Differences in Cost Structure and Operative Time.

To compare perioperative outcomes and hospital cost structure between Hugo RAS and da Vinci Xi for benign simple hysterectomy using a common institutional accounting framework.

Published: June 17, 2026, midnight
NMR-based serum metabolite and lipoprotein profiling for endometriosis across clinically relevant and physiological comparator settings: assessment of diagnostic utility and exploratory biological signals.

Reliable non-invasive biomarkers for endometriosis remain unavailable in routine practice, and their translational value depends on performance in symptomatic referral populations rather than only against healthy controls. We evaluated Nuclear …

Published: June 17, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!